...Huihong Dou; Yuanhan Qin; Guoli Chen; Yanjun Zhao Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies. In this study, a systematic meta-analysis was performed to assess the effectiveness...

... = 14; deferiprone, n = 11, and deferasirox, n = 15) or in certain combinations (deferoxamine plus deferasirox, n = 2, and deferiprone plus deferoxamine, n = 18). Ferritin serum levels were not equally distributed among patients subjected to the different chelation schedules (p = 0.02). Patients...

... deferasirox efficacy and safety in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemias. A 1-year, open-label, multicenter, single-arm, phase II trial was performed with deferasirox (10-40 mg/kg/day, based on transfusion frequency and therapeutic goals), including...

... (ICT) is important in patients with aplastic anemia (AA) who require blood transfusions as supportive management. With the introduction of the oral iron chelator deferasirox, ICT has become more widely available and feasible. We studied 4 adult AA patients who had transfusion-induced iron overload...

...Rodolfo Cancado; Maria Cristina A. Olivato; Paula Bruniera; Gilberto Szarf; Roberto de Moraes Bastos; Murilo Rezende Melo; Carlos Chiattone The efficacy and safety of a 2-year treatment with deferasirox was evaluated in 31 patients with sickle cell anemia and transfusional iron overload. At 24...

...M. Nagler; M. Gregor; W.A. Wuillemin We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe...

...Paolo Ricchi; Silvia Costantini; Anna Spasiano; Tiziana Di Matola; Patrizia Cinque; Luciano Prossomariti In this report, we present a case of a spontaneous pregnancy in a 42-year-old thalassemic woman referred to our Microcythemic Unit while she was on deferasirox (DFX) therapy. The patient had...

...A. Quarta; A. Melpignano; G. Quarta Iron overload sometimes complicates the clinical course of bone marrow transplantation and can cause damage to liver and heart function. A patient with post-transplantation secondary hemochromatosis was treated with deferasirox, which not only normalized ferritin...

...Ali Taher; Abdullah Al Jefri; Mohsen Saleh Elalfy; Kusai Al Zir; Shahina Daar; Diana Rofail; Jean François Baladi; Dany Habr; Ulrike Kriemler-Krahn; Amal El-Beshlawy Patient-reported outcomes of once-daily oral deferasirox (Exjade®) in iron-overloaded patients with β-thalassemia not achieving...

...Paolo Ricchi; Massimiliano Ammirabile; Anna Spasiano; Silvia Costantini; Patrizia Cinque; Tiziana Di Matola; Luciano Prossomariti In this report we present a 37-year-old thalassemia patient with hyperferritinemia referred to our Microcytemia Center at the beginning of deferasirox (DFX) therapy...

...M.D. Cappellini; A. Taher Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Deferasirox Iron chelation Myelodysplastic syndrome Letter...

...Maya Otto-Duessel; Casey Brewer; Ignacio Gonzalez; Hanspeter Nick; John C. Wood Introduction: Combined therapy with deferoxamine (DFO) and deferasirox (DFX) may be performed empirically when DFX monotherapy fails. Given the lack of published data on this therapy, the study goal was to assess...

... available for chelation therapy, e.g. oral once-daily administration of the iron chelator deferasirox. In 3 patients with MDS and 1 patient with PMF, deferasirox therapy resulted in an improvement in the hemoglobin level and a reduction in transfusion dependence. Our data open new insights regarding...